Filtered By:
Therapy: Stem Cell Therapy

This page shows you your search results in order of date. This is page number 10.

Order by Relevance | Date

Total 3267 results found since Jan 2013.

Understanding the effects of mesenchymal stromal cell therapy for treating osteoarthritis using an in vitro co-culture model
Eur Cell Mater. 2023 Jun 19;45:143-157. doi: 10.22203/eCM.v045a10.ABSTRACTOsteoarthritis (OA) is a leading cause of chronic pain and disability, for which there is no cure. Mesenchymal stromal cells (MSCs) have been used in clinical trials for treating OA due to their unique ability to generate paracrine anti-inflammatory and trophic signals. Interestingly, these studies have shown mainly short-term effects of MSCs in improving pain and joint function, rather than sustained and consistent benefits. This may reflect a change or loss in the therapeutic effects of MSCs after intra-articular injection. The present study aimed ...
Source: European Cells and Materials - June 19, 2023 Category: Cytology Authors: V Shang J Li C B Little J J Li Source Type: research

Non-osteopenic Bone Pathology After Allo-hematopoietic Stem Cell Transplantation in Patients with Inborn Errors of Immunity
ConclusionNon-osteopenic bone pathology in long-term survivors of allo-HSCT for IEI is not rare. Most patients did not present with complaints until at least 5  years post-HSCT highlighting the need for ongoing bone health assessment for patients with IEI. Children presenting with stunted growth and bone pathology post-HSCT should undergo skeletal survey to rule out development of post-HSCT skeletal dysplasia. Increased rates and complexity of bone pathol ogy were seen amongst patients with Wiskott-Aldrich syndrome.
Source: Journal of Clinical Immunology - June 16, 2023 Category: Allergy & Immunology Source Type: research

FDA approves Roche ’s Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma
Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate and a median duration of response of 1.5 years (18.4 months)1Given over a fixed period of time,Columvi provides patients with a treatment end date and potential time off treatmentColumvi is part of Roche ' s industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approvedLunsumioto treat follicular lymphomaBasel, 16 June 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved ...
Source: Roche Investor Update - June 16, 2023 Category: Pharmaceuticals Source Type: news

Effects of Puerarin ‐Loaded Tetrahedral Framework Nucleic Acids on Osteonecrosis of the Femoral Head
In this study, tFNAs as Pue carriers is used and synthesized a tFNA/Pue complex (TPC) that exhibited better stability, biocompatibility, and tissue utilization than free Pue. A dexamethasone (DEX)-treated BMSC model in vitro and a methylprednisolone (MPS)-induced ONFH model in vivo is also established, to explore the regulatory effects of TPC on osteogenesis and apoptosis of BMSCs. This findings showed that TPC can restore osteogenesis dysfunction and attenuated BMSC apoptosis induced by high-dose glucocorticoids (GCs) through the hedgehog and Akt/Bcl-2 pathways, contributing to the prevention of GC-induced ONFH in rats. T...
Source: Small - June 15, 2023 Category: Nanotechnology Authors: Yuxuan Zhao, Songhang Li, Maogeng Feng, Mei Zhang, Zhiqiang Liu, Yangxue Yao, Tianxu Zhang, Yueying Jiang, Yunfeng Lin, Xiaoxiao Cai Tags: Research Article Source Type: research

Growth differentiation factor 5 inhibits lipopolysaccharide-mediated pyroptosis of nucleus pulposus mesenchymal stem cells via RhoA signaling pathway
CONCLUSION: These findings suggest that GDF-5 plays an important role in inhibiting the pyroptosis of NPMSCs and GDF-5 may have potential for degenerative disc disease gene-targeted therapy in the future.PMID:37310547 | DOI:10.1007/s11033-023-08547-6
Source: Molecular Biology Reports - June 13, 2023 Category: Molecular Biology Authors: Chao Zhu Qing Zhou Zuqiang Wang Junyou Zhang Cheng Xu Dike Ruan Source Type: research

Therapeutic effects and mechanism of human amnion-derived mesenchymal stem cells on hypercoagulability in a uremic calciphylaxis patient
Ren Fail. 2023 Dec;45(1):2218483. doi: 10.1080/0886022X.2023.2218483.ABSTRACTCalciphylaxis is a rare cutaneous vascular disease that manifests with intolerable pains, non-healing skin wounds, histologically characterized by calcification, fibrointimal hyperplasia, and microvessel thrombosis. Currently, there are no standardized guidelines for this disease. Recent studies have recognized a high prevalence of thrombophilias and hypercoagulable conditions in calciphylaxis patients. Here, we report a case of uremic calciphylaxis patient whom was refractory to conventional treatments and then received a salvage strategy with in...
Source: Renal Failure - June 9, 2023 Category: Urology & Nephrology Authors: Anning Bian Xiaoxue Ye Jing Wang Ming Zeng Jiayin Liu Kang Liu Song Ning Yugui Cui Shaowen Tang Xueqiang Xu Yanggang Yuan Zhonglan Su Yan Lu Jing Zhou Xiang Ma Guang Yang Yaoyu Huang Feng Chen Youjia Yu Mufeng Gu Xiaolin Lv Ling Wang Jing Zhao Xiuqin Wang Source Type: research

Safe and Durable Treatment of Dentin Hypersensitivity via Nourishing and Remineralizing Dentin Based on β‐Chitooligosaccharide Graft Derivative
A safe and durable treatment of dentin hypersensitivity via nourishing and remineralizing dentin based onβ-chitooligosaccharide graft derivative (CAD) is developed. CAD infiltrated into dentin tubules and repair the glycosaminoglycan film that regulates mineralization. Mechanistically, CAD regulates the level of inflammatory factors, promotes the proliferation and differentiation of dental pulp stem cells, and remineralizes dentinal tubules to form dense hydroxyapatite. AbstractDentin hypersensitivity (DH) is a common symptom of various dental diseases that usually produces abnormal pain with external stimuli. Various des...
Source: Small - June 9, 2023 Category: Nanotechnology Authors: Bailei Li, Jiren Xu, Ruixue Ai, Haixing Zhang, Mingjun Wei, Rongqing Zhang, Chunling Bao, Wenhui Wu Tags: Research Article Source Type: research

Over-expression of microRNA-145 elevating autophagy activities via downregulating FRS2 expression
CONCLUSION: The miR-145 acts as a protective factor against chondrocytes by regulating miR-FRS2-autophagy axis. The decrease of miR-145 in articular synovial fluid may turn out to be an important marker for early diagnosis of OA, and modulation of miR-145 may represent a promising therapeutic strategy for OA.PMID:37264620 | DOI:10.2174/1386207326666230602090848
Source: Combinatorial Chemistry and High Throughput Screening - June 2, 2023 Category: Chemistry Authors: Tian Ke Deng Bin Han Xiaodong Zheng Haiyi Lin Tao Zhimeng Wang Zhang Yuanmin Wang Guodong Source Type: research